Outcomes cannot be attributed to the pacing strategy alone, as age, comorbidities, disease-modifying treatments such as transthyretin stabilizers (e.g., tafamidis), and heart failure therapies all influence disease progression and competing risks of morbidity and mortality. Here, TTR is linked to heart failure.